Kolon kanserinde eksozomal mirna moleküllerinin araştırılması


Thesis Type: Postgraduate

Institution Of The Thesis: Istanbul University, Health Sciences Institute, Onkoloji Enstitüsü Bölümü, Turkey

Approval Date: 2024

Thesis Language: Turkish

Student: SÜMEYYE ONAT

Supervisor: Şeref Buğra Tunçer

Open Archive Collection: AVESIS Open Access Collection

Abstract:

Colorectal cancers rank third worldwide in incidence and second in mortality. Because colon tumors are slow-growing, they often reach an advanced stage before becoming symptomatic. Therefore, screening procedures are used to help reduce the morbidity and mortality of colon cancer. Currently, there are several colon cancer screening methods available, such as stool tests, colonoscopy, and double-contrast barium enemas to detect cancer and/or precancerous lesions. However, some of these methods are invasive or have limited sensitivity and specificity. To overcome these clinical challenges, there is still a need today to discover new, reliable, non-invasive, and highly sensitive diagnostic biomarkers specific to colon cancer. Exosomes are nano-scale extracellular vesicles surrounded by a lipid bilayer that carry various biomolecules produced in the endosomal compartment of most eukaryotic cells. Because cancer cells produce more exosomes than normal cells, exosomes are thought to be useful as a diagnostic tool in cancer screenings. Similarly, previous studies have shown that cells actively secrete miRNAs into the extracellular environment via exosomes, and these molecules function as biological messengers that communicate between cells, contributing to drug resistance, immunomodulation, and metastasis in various cancer types. Therefore, the discovery of effective biomarkers in exosomes for early cancer diagnosis is of widespread interest in the scientific community. In this study, it is aimed to identify potential biomarkers in colon cancer by comparing the expression levels of exosomal miR-769-5p, miR-3937, miR-99a-5p, and miR-30b-3p microRNAs, which have not been previously studied together, obtained from blood serum of patients with primary and metastatic colon cancer and healthy controls. Thus, with the help of highly sensitive, non-invasive, and colon cancer-specific diagnostic biomarkers, a definitive diagnosis and information about the prognosis of the disease can be obtained without the need for invasive procedures that would hinder the patient's quality of life.